Alan D. Irvine

Active 1997–2025

174
Papers
32,928
Citations
86
h-index
163
i10-index

Citations

Citations per year for Alan D. Irvine1964: 2 citations1975: 2 citations1983: 1 citations1986: 9 citations1992: 3 citations1997: 4 citations1998: 7 citations1999: 10 citations2000: 22 citations2001: 26 citations2002: 34 citations2003: 31 citations2004: 46 citations2005: 33 citations2006: 74 citations2007: 151 citations2008: 216 citations2009: 256 citations2010: 233 citations2011: 342 citations2012: 288 citations2013: 321 citations2014: 308 citations2015: 235 citations2016: 264 citations2017: 304 citations2018: 327 citations2019: 1,028 citations2020: 1,085 citations2021: 1,275 citations2022: 1,194 citations2023: 1,075 citations2024: 1,677 citations2025: 842 citations2026: 3 citations1965–1974: no citations, so these years are not shown1976–1982: no citations, so these years are not shown1984–1985: no citations, so these years are not shown1987–1991: no citations, so these years are not shown1993–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,535 citing papers, 20% of this breakdownGermany: 993 citing papers, 7.8% of this breakdownUnited Kingdom: 992 citing papers, 7.8% of this breakdownChina: 959 citing papers, 7.6% of this breakdownJapan: 599 citing papers, 4.7% of this breakdownItaly: 496 citing papers, 3.9% of this breakdownFrance: 490 citing papers, 3.9% of this breakdownCanada: 437 citing papers, 3.5% of this breakdownNetherlands: 433 citing papers, 3.4% of this breakdownSwitzerland: 343 citing papers, 2.7% of this breakdownSpain: 321 citing papers, 2.5% of this breakdownAustralia: 298 citing papers, 2.4% of this breakdown
0%20%Other 29.8%

Fields

  • Medicine68.9%
  • Biochemistry, Genetics and Molecular Biology14.5%
  • Immunology and Microbiology10.7%
  • Pharmacology, Toxicology and Pharmaceutics1.4%
  • Neuroscience1.3%
  • Environmental Science0.7%
  • Other2.5%

Topics

  • Dermatology and Skin Diseases17.9%
  • Allergic Rhinitis and Sensitization7.9%
  • Asthma and respiratory diseases6.2%
  • Psoriasis: Treatment and Pathogenesis5.4%
  • Food Allergy and Anaphylaxis Research4%
  • Skin and Cellular Biology Research1.9%
  • Other56.7%

Coauthors

All papers

Open in search
  1. Atopic dermatitis

    Authors: , , - The Lancet 2020 cited by 1,763

  2. Atopic dermatitis

    Authors: , , , , - Nature Reviews Disease Primers 2018 cited by 1,481

  3. The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation

    Authors: , , , , , , , , , , , , , - Cell Metabolism 2020 cited by 588

  4. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet 2021 cited by 543

  5. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2006 cited by 2,950

  6. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 314

  7. Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship

    Authors: , , - Trends in Microbiology 2017 cited by 495

  8. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

    Authors: , , , , , , , , , , , , , - RMD Open 2023 cited by 210

  9. Filaggrin Mutations Associated with Skin and Allergic Diseases

    Authors: , , - New England Journal of Medicine 2011 cited by 1,204

  10. The microbiome in patients with atopic dermatitis

    Authors: , , , , , , , - Journal of Allergy and Clinical Immunology 2018 cited by 531

  11. The atopic march and atopic multimorbidity: Many trajectories, many pathways

    Authors: , , , - Journal of Allergy and Clinical Immunology 2018 cited by 429

  12. Filaggrin in the frontline: role in skin barrier function and disease

    Authors: , , , - Journal of Cell Science 2009 cited by 872

  13. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Suzannah J. Bumpstead, Sarah Hunt, Simon Potter, Sarah Edkins, Cordelia Langford, Leena Peltonen, Panos Deloukas, Juan P. Casas, Michael J. Cork, Rachid Tazi‐Ahnini, Aiden Corvin, Gilean McVean, Alexander Dilthey, Gil McVean, Loukas Moutsianas, Stephen Leslie, Audrey Duncanson, Xavier Estivill, Eva Riveira‐Muñoz, Brian Kirby, Oliver FitzGerald, Emiliano Giardina, Giuseppe Novelli, Wolfgang Weger, Angelika Hofer, Wolfgang Salmhofer, André Reis, Ulrike Hüffmeier, Alan D. Irvine, Janusz Jankowski, Jesús Lascorz, A. David Burden, Joyce Leman, Katarina Wolk, Lotus Mallbris, Mona Ståhle, Hugh S. Markus, W.H. Irwin McLean, Lena Samuelsson, Colin N A Palmer, Carlo Perricone, Robert Plomin, Rotraut Mößner, Åsa Torinsson Naluai, Lena Samuelsson, Heiko Traupe, Carlo Perricone, Robert Plomin, Ramón M. Pujol, Adrian Hayday, Stephen Sawcer, Juha Kere, Catherine Smith, Heiko Traupe - Nature Genetics 2010 cited by 1,058

  14. The role of filaggrin in atopic dermatitis and allergic disease

    Authors: , - Annals of Allergy Asthma & Immunology 2019 cited by 314

  15. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Seth J. Orlow, Bianca Maria Piraccini, Adriana Rakowska, Pascal Reygagne, Janet L. Roberts, Lidia Rudnicka, Jerry Shapiro, Pooja Sharma, Antonellá Tosti, Annika Vogt, Martin Wade, Leona Yip, Abraham Zlotogorski, Rodney Sinclair - Journal of the American Academy of Dermatology 2020 cited by 204

  16. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group

    Authors: , , , , , , , , , , , , , , , - British Journal of Dermatology 2019 cited by 214

  17. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

    Authors: , , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2022 cited by 63

  18. Filaggrin and beyond

    Authors: , - Annals of Allergy Asthma & Immunology 2023 cited by 91

  19. Clinical and genetic differences between pustular psoriasis subtypes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesca Capon - Journal of Allergy and Clinical Immunology 2018 cited by 268

  20. Early initiation of short‐term emollient use for the prevention of atopic dermatitis in high‐risk infants—The STOP‐AD randomised controlled trial

    Authors: , , , , , , , , - Allergy 2022 cited by 96

  21. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2019 cited by 201

  22. Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year

    Authors: , , , , , , , , , - Journal of Allergy and Clinical Immunology 2016 cited by 345

  23. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2017 cited by 236

  24. The role of Janus kinase signaling in the pathology of atopic dermatitis

    Authors: , , , , , , , - Journal of Allergy and Clinical Immunology 2023 cited by 97